DK1423124T3 - Lyofiliseret formulering indeholdende olanzapin - Google Patents

Lyofiliseret formulering indeholdende olanzapin

Info

Publication number
DK1423124T3
DK1423124T3 DK02749634T DK02749634T DK1423124T3 DK 1423124 T3 DK1423124 T3 DK 1423124T3 DK 02749634 T DK02749634 T DK 02749634T DK 02749634 T DK02749634 T DK 02749634T DK 1423124 T3 DK1423124 T3 DK 1423124T3
Authority
DK
Denmark
Prior art keywords
formulation containing
lyophilized formulation
containing olanzapine
olanzapine
lyophilized
Prior art date
Application number
DK02749634T
Other languages
Danish (da)
English (en)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven L Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1423124T3 publication Critical patent/DK1423124T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK02749634T 2001-07-20 2002-07-05 Lyofiliseret formulering indeholdende olanzapin DK1423124T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
DK1423124T3 true DK1423124T3 (da) 2007-12-03

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749634T DK1423124T3 (da) 2001-07-20 2002-07-05 Lyofiliseret formulering indeholdende olanzapin

Country Status (33)

Country Link
US (1) US20040176357A1 (hr)
EP (1) EP1423124B1 (hr)
JP (1) JP2004537546A (hr)
KR (1) KR20040017330A (hr)
CN (1) CN1537007A (hr)
AR (1) AR036180A1 (hr)
AT (1) ATE369137T1 (hr)
AU (1) AU2002320134B2 (hr)
BR (1) BR0211250A (hr)
CA (1) CA2448724A1 (hr)
CO (1) CO5540279A2 (hr)
CY (1) CY1107759T1 (hr)
CZ (1) CZ200484A3 (hr)
DE (1) DE60221674T2 (hr)
DK (1) DK1423124T3 (hr)
EA (1) EA006506B1 (hr)
ES (1) ES2289126T3 (hr)
HK (1) HK1066484A1 (hr)
HR (1) HRP20040037A2 (hr)
HU (1) HUP0401157A3 (hr)
IL (1) IL159098A0 (hr)
MX (1) MXPA04000541A (hr)
MY (1) MY135452A (hr)
NZ (1) NZ529667A (hr)
PE (1) PE20030281A1 (hr)
PL (1) PL366614A1 (hr)
PT (1) PT1423124E (hr)
SI (1) SI1423124T1 (hr)
SK (1) SK182004A3 (hr)
SV (1) SV2003001179A (hr)
UA (1) UA80095C2 (hr)
WO (1) WO2003007912A2 (hr)
ZA (1) ZA200400798B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
BR112020013750A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059947T3 (es) * 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
ATE369137T1 (de) 2007-08-15
ZA200400798B (en) 2005-07-27
HUP0401157A2 (hu) 2004-10-28
CA2448724A1 (en) 2003-01-30
IL159098A0 (en) 2004-05-12
PL366614A1 (en) 2005-02-07
PT1423124E (pt) 2007-10-29
CN1537007A (zh) 2004-10-13
WO2003007912A3 (en) 2003-05-01
CY1107759T1 (el) 2013-06-19
SK182004A3 (en) 2004-09-08
UA80095C2 (en) 2007-08-27
DE60221674T2 (de) 2008-04-30
WO2003007912A2 (en) 2003-01-30
EA006506B1 (ru) 2005-12-29
US20040176357A1 (en) 2004-09-09
KR20040017330A (ko) 2004-02-26
NZ529667A (en) 2006-02-24
AR036180A1 (es) 2004-08-18
ES2289126T3 (es) 2008-02-01
EP1423124B1 (en) 2007-08-08
JP2004537546A (ja) 2004-12-16
EP1423124A2 (en) 2004-06-02
DE60221674D1 (de) 2007-09-20
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
BR0211250A (pt) 2004-07-27
EA200400211A1 (ru) 2004-06-24
CZ200484A3 (cs) 2005-01-12
PE20030281A1 (es) 2003-03-27
HUP0401157A3 (en) 2008-01-28
CO5540279A2 (es) 2005-07-29
HK1066484A1 (en) 2005-03-24
HRP20040037A2 (en) 2004-06-30
MXPA04000541A (es) 2004-05-04
AU2002320134B2 (en) 2007-04-05
SI1423124T1 (sl) 2008-02-29

Similar Documents

Publication Publication Date Title
NO20033384L (no) Farmasoytisk formulering
ITTO20010008A0 (it) Formulazione farmaceutica
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20033785L (no) Farmasöytisk formulering
BR0210619A (pt) composição
NO20035627D0 (no) Farmasöytisk formulering
FI20022128A0 (fi) Farmaseuttinen koostumus
DK1423124T3 (da) Lyofiliseret formulering indeholdende olanzapin
ITTO20020744A0 (it) Composizione
ITTO20020745A0 (it) Composizione
NO20040250L (no) Metyl-tieno-benzodiazepinlyofilisert formulering
NO20041236L (no) Farmasoytisk formulering
SE0100477D0 (sv) Novel formulation
SE0100478D0 (sv) Novel formulation
SE0100199D0 (sv) New formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
DK1307264T3 (da) Hidtil ukendt farmaceutisk præparat
FI5468U1 (fi) Farmaseuttinen koostumus
ITTO20020746A0 (it) Composizione